18 and older, any sex, with Myopia or Hyperopia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Subjective Overall ScorePrimary· 15 minutes
Subjective overall score was assessed using 0-100 visual analogue scale, where 0=Extremely poor, cannot use lenses and 100=Excellent, highly impressed with these lenses overall
Group
Value
95% CI
Lens 1
84.7
± 15.5
Lens 2
82.5
± 14.6
Subjective ComfortSecondary· 15 minutes
Subjective comfort score was assessed using 0-100 visual analogue scale, where 0=Causes pain, cannot be tolerated and 100=Excellent, cannot be felt
Group
Value
95% CI
Lens 1
86.4
± 16.4
Lens 2
86.6
± 13.5
Subjective VisionSecondary· 15 minutes
Subjective vision score was assessed using a 0-100 visual analogue scale, where 0=Unacceptable, lens cannot be worn and 100=Excellent, unaware of any visual loss
Group
Value
95% CI
Lens 1
85.8
± 14.9
Lens 2
82.7
± 15.9
Sponsor's own description
The study objective was to gather short-term clinical performance data for two soft contact lenses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CooperVision, Inc.
Last refreshed: 10 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05741450.